Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Adrenocortical Carcinoma|ACC|Metastatic Adrenocortical Carcinoma
RADIATION: Ablative Radiotherapy|DRUG: Pembrolizumab
Number of participants evaluated for AEs, The primary objective of this pilot study is to evaluate the safety of treatment with ablative Radiotherapy/RT followed by pembrolizumab in patients with advanced Adrenocortical Carcinoma/ACC by evaluating treatment related adverse events. AEs will be recorded according to "Common Terminology Criteria for Adverse Events" v5.0 (CTCAE)., up to 1 year
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.